Takeda Pharmaceutical Files 6-K Report

Ticker: TKPHF · Form: 6-K · Filed: Jul 8, 2025 · CIK: 1395064

Takeda Pharmaceutical Co Ltd 6-K Filing Summary
FieldDetail
CompanyTakeda Pharmaceutical Co Ltd (TKPHF)
Form Type6-K
Filed DateJul 8, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-private-issuer, sec-filing

TL;DR

Takeda filed a 6-K on 7/8/25, standard foreign issuer report.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on July 8, 2025, reporting as a foreign private issuer. The filing indicates Takeda will file its annual reports under Form 20-F. No specific financial or operational details beyond the filing type and date were provided in this excerpt.

Why It Matters

This filing serves as a routine update for investors and regulators, confirming Takeda's status as a foreign private issuer and its adherence to reporting requirements.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material information that would typically impact risk.

Key Players & Entities

  • Takeda Pharmaceutical Company Limited (company) — Filer of the 6-K report
  • 0001395064-25-000113 (other) — Accession number for the filing
  • 001-38757 (other) — SEC file number for Takeda
  • 20-F (document) — Form under which Takeda files annual reports
  • 6-K (document) — Form type filed on July 8, 2025

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, used to furnish information which the registrant may be required to disclose to any stock exchange on which its securities are traded.

What is Takeda Pharmaceutical Company Limited's SEC file number?

Takeda Pharmaceutical Company Limited's SEC file number is 001-38757.

Under which form does Takeda file its annual reports?

Takeda Pharmaceutical Company Limited files its annual reports under Form 20-F.

What is the accession number for this specific filing?

The accession number for this filing is 0001395064-25-000113.

What is Takeda's principal executive office address?

Takeda's principal executive office is located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 8, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.